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Background: Several systematic reviews have summarized the evidence for specific treatments of primary care
patients suffering from depression. However, it is not possible to answer the question how the available treatment
options compare with each other as review methods differ. We aim to systematically review and compare the
available evidence for the effectiveness of pharmacological, psychological, and combined treatments for patients
with depressive disorders in primary care.
Methods/Design: To be included, studies have to be randomized trials comparing antidepressant medication
(tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), hypericum extracts, other agents) and/or
psychological therapies (e.g. interpersonal psychotherapy, cognitive therapy, behavioural therapy, short dynamically-
oriented psychotherapy) with another active therapy, placebo or sham intervention, routine care or no treatment
in primary care patients in the acute phase of a depressive episode. Main outcome measure is response after
completion of acute phase treatment. Eligible studies will be identified from available systematic reviews, from
searches in electronic databases (Medline, Embase and Central), trial registers, and citation tracking. Two reviewers
will independently extract study data and assess the risk of bias using the Cochrane Collaboration’s corresponding
tool. Meta-analyses (random effects model, inverse variance weighting) will be performed for direct comparisons of
single interventions and for groups of similar interventions (e.g. SSRIs vs. tricyclics) and defined time-windows (up
to 3 months and above). If possible, a global analysis of the relative effectiveness of treatments will be estimated
from all available direct and indirect evidence that is present in a network of treatments and comparisons.
Discussion: Practitioners do not only want to know whether there is evidence that a specific treatment is more
effective than placebo, but also how the treatment options compare to each other. Therefore, we believe that a
multiple treatment systematic review of primary-care based randomized controlled trials on the most important
therapies against depression is timely.
Background
Epidemiological studies indicate that depressive disor-
ders are highly prevalent in the general population
worldwide [1]. Most cases are seen and managed in pri-
mary care, and only a small proportion of these are
referred to specialty care [2]. A number of studies sug-
gest that primary care patients with depressive disorders
are less severely depressed [3], experience a milder
course of illness [4], have a distinct symptom profile
with more complaints of fatigue and somatic symptoms
[5], and are more likely to have accompanying physical
complaints [6] than patients referred to specialty mental
health care.
The cornerstones of antidepressant treatment are
pharmacotherapy and psychological interventions [7].
However, while the vast majority of patients with
depression are dealt with in primary care, most of the
research findings upon which decisions are made have
involved secondary care patients. It is not fully clear
whether the findings from trials in specialty settings can
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any medium, provided the original work is properly cited.be generalized to primary care. Meta-analyses restricted
to primary care patients have been performed for SSRIs
and tricyclics compared to placebo [8,9], SSRIs com-
pared to tricyclics [10], and psychological interventions
[11,12]. They concluded that these treatments are effec-
tive in primary care settings. In some countries a rele-
vant proportion of primary care patients with depressive
symptoms is treated with hypericum extracts [13]. The
co-morbidity and symptom pattern of primary care
patients described in recent studies [14,15] fits well to
the traditional indications of hypericum extracts (psy-
cho-vegetative disorders, depressive disorders, anxiety
and/or nervous agitation) [16]. Systematic reviews of
hypericum extracts include a considerable number of
randomized trials in primary care patients [17,18]. How-
ever, in these reviews the results of trials in primary and
secondary care settings were pooled and not analyzed
separately. Systematic reviews on music therapy, acu-
puncture, exercise, relaxation, and family therapy for
treating depression published in the Cochrane Database
of Systematic Reviews include only few or no trials con-
ducted in primary care settings [19-23].
The systematic reviews and meta-analyses cited above
[8-12,17,18] summarize the majority of the available
randomized trials of depression treatments in primary
care. However, it is not possible to answer the question
how the available treatment options compare with each
other (i.e., whether some treatments are superior to
others in primary care). Traditional meta-analyses are
restricted to the direct comparison of two interventions
b yp o o l i n gd a t ao n l yf r o mt r i als with similar treatment
arms. By consequence, they allow no decision about the
relative effectiveness of two treatments, if they have not
yet been directly compared in at least one randomized
controlled trial (RCT). However, in case of insufficient
or missing direct comparisons of available interventions
the utility of indirect evidence may be considered. For
example, RCTs of treatment A vs. placebo and treat-
ment B vs. placebo would provide indirect estimates on
the comparative effectiveness of A vs. B through the
common reference placebo. The inclusion of more inter-
ventions would result in more complex networks and
involve more complex indirect comparisons.
Network (or multiple/mixed treatment) meta-analyses
are an enhancement of the traditional meta-analysis
methodology to more than two interventions [24]. They
estimate the comparative effectiveness between two
treatments based on all available direct and indirect evi-
dence that is available in a network of treatments and
comparisons. Besides augmenting validity of compari-
sons between available treatments through including
indirect evidence, network meta-analyses allow for a for-
mal assessment of evidence inconsistencies. Not least,
they suggest a ranking of interventions according to
their relative effectiveness, which may be of high rele-
vance for clinical decision making. Network meta-ana-
lyses have been performed, for example, to compare
newer antidepressant agents [25,26]. However, most
trials included in these research syntheses were not per-
formed in the primary care setting. This is of impor-
tance as patients in primary care might differ from
those in secondary care.
For results of network meta-analyses to be valid three
important pre-conditions should be met [27]: 1) the
findings of each of the meta-analyses of the direct com-
parisons should be homogeneous (not suggesting that
trials investigated slightly different questions); 2) for the
indirect comparisons to be valid, patients included in
the separate subgroups of trials need to be sufficiently
similar; and 3) if both direct and indirect comparisons
are available the pooled estimates for these need to be
consistent. It might be that these pre-conditions will not
be met in case of the primary care trials of various treat-
ments for depression.
Objectives
We will systematically review all randomized trials
investigating treatments for depression performed in pri-
mary care settings. As we will use the same review
methods across all treatments, a comparison of the evi-
dence regarding effectiveness, feasibility, and safety will
be possible. If adequate, we aim to perform a formal
multiple treatment meta-analysis.
Methods/Design
Criteria for selecting studies for this review
Type of study
Inclusion will be restricted to trials in which allocation
of patients to groups was explicitly randomized. Trials
in which a clearly inadequate method or a pseudo-ran-
dom method was used (e.g. alternation) will be
excluded. Trials with a post-randomization period of
less than 4 weeks will be excluded.
Types of participants
To be included studies must have recruited adults (18
years or older). Studies with a majority (more than 50%)
of participants under 18 years will be excluded. Patients
must have been recruited from a primary care setting
(primary care clinics, private practices of general practi-
tioners, internists or other non-psychiatrists providing
primary care in the respective country). Trials in mixed
settings (for example, some patients recruited by general
practitioners, some by psychiatrists in private practice)
will be excluded unless subgroup data on primary care
patients are available. Included patients had to suffer
from prevalent or incident unipolar depressive disorder.
Studies using ICD 10 (International Classification of
Disease - WHO, tenth revision) for operationalizing
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the categories F32.×/F33.× or F34.1, studies using DSM
IV (Diagnostic and Statistical Manual - American Psy-
chiatric Association) will be included if patients are clas-
sified under the categories 296.2×/296.3× or 300.4. As
older or pragmatic studies in primary care often do not
use such classification we will also include studies in
which the provider considered patients to suffer from
depression without applying a formal classification sys-
tem if the diagnosis is assessed to be valid by the
reviewers. Studies focussing exclusively on depressive
symptoms in a specific group of patients suffering pri-
marily from another condition (e.g., depressive symp-
toms in patients with cardiovascular disease, Alzheimer
disease, or postpartum depression) will be excluded
whereas studies including depressive primary care
patients which also suffer from a variety of other condi-
tions will be included. Studies in mixed patient popula-
tions (e.g. some with depression and some with
cyclothymia) will be included only if findings for the
subgroup of patients with depression are available
separately.
Types of interventions
Based on preliminary searches we have decided to focus
on interventions which are widespread and are included
in recent guidelines for outpatient care [7,28]: tricyclic
and tetracyclic antidepressants, selective serotonine
reuptake inhibitors, monoamino-oxidase inhibitors,
newer agents such as venlafaxine or mirtazepine, hyperi-
cum extracts, psychological and psychosocial therapies
(interpersonal psychotherapy, cognitive therapy, beha-
vioural therapy, short dynamically-oriented psychother-
apy, counselling, etc.) or a combination of
pharmacological and psychological therapy. If screening
searches identify a relevant number of primary care
trials on other interventions the inclusion criteria will be
adapted. We will not include trials which investigate the
management of treatment (for example interprofessional
case-management) instead of the depression therapy as
in such trials typically allow a mixture of different treat-
ment options both in intervention and control groups.
Types of comparators
Trials will be included if they compare one of the inter-
ventions listed above to at least one of the following
options: a) directly versus one of the other interventions
listed under “Interventions"; b) versus placebo, sham or
attention control procedures; c) versus usual care; d)
versus waiting list or no treatment.
Types of outcome measures
To be included trials have to report results on at least
one of the following outcomes: response to treatment,
remission, mean score on a depression scale (post-treat-
ment or change from baseline), quality of life, patient
global assessment, number of patients with adverse or
side effects, number of patients discontinuing treatment
or dropping out from the study (for any reasons and/or
lack of improvement and/or adverse effects).
Search methods for identification of studies
In a first step a basic collection of studies will be com-
piled from existing systematic reviews restricted to ran-
domized trials in primary care of tricyclic
antidepressants and SSRIs [8-10], psychological therapies
[11,12], as well as from a Cochrane review on hyperi-
cum extracts [17,18]. In order to identify further poten-
tially relevant treatment interventions we will screen
meta-analyses of other treatments for trials performed
in primary care. Furthermore, we will screen the refer-
ences yielded by a PubMed search for randomized trials
in primary care patients with depressive disorders. We
then will perform database searches without language
restrictions in CENTRAL, MEDLINE and EMBASE. The
search strategy will be developed in consultation with an
information specialist and tested using the trials identi-
fied for the basic collection. All databases will be
searched from 1980 onwards (older trials will not be
searched systematically due to different diagnostic classi-
fications and concerns regarding study quality) using
both standard vocabulary (e.g. MeSH) and keywords.
For searches a disease-component will be combined
(AND) with a setting-component and a design-compo-
nent. RCTs (design-component) will be identified using
the Cochrane Highly Sensitive Search Strategy for iden-
tifying randomized controlled trials.
We will search trial registers (Clinicaltrials.gov, Inter-
national Clinical Trials Registry Platform (ICTRP), Ger-
man Clinical Trial Register) to identify ongoing and
unpublished studies. Furthermore, we will examine
reference lists of identified studies.
Study selection process
Following a screening of titles and abstracts by one
reviewer to exclude clearly irrelevant papers, the deci-
sion to include or exclude a potentially eligible study
will be based on the review of full texts independently
by at least two reviewers using a structured form with
the selection criteria listed above. Disagreements
between reviewers will be documented and resolved by
discussion. If consensus cannot be achieved between the
original reviewers, an additional reviewer will be asked
to make a final decision.
Data extraction
Primary study characteristics and results will be
extracted by at least two independent reviewers using a
pre-tested form. Extraction will be made in a manner
similar to the Cochrane review of hypericum extracts of
depression [18]. In particular, we will document
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tion of episodes, baseline depression scores, country of
origin, number and type of study centres, numbers of
patients who were randomized and analyzed and who
completed protocols, the number and reasons for drop-
outs and withdrawals, numbers of patients reporting
adverse effects, and the number and type of adverse
effects that were reported. We will extract numbers of
patients who were classified as responders based on
score improvements on the Hamilton Rating Scale for
Depression (HAMD; first preference), the Montgomery-
Asberg Depression Rating Scale (MADRS; second pre-
ference), the Clinical Global Impression Index (CGI;
subscale global improvement rating as at least “much
improved"; third preference), or any other clinical
response measurement. We will try to obtain missing
information from authors/sponsors. Means and standard
deviations for observer-rated (e.g. HAMD, Montgomery-
Asberg Depressions Rating Scale) or patient-rated scales
(e.g. Depression Scale von Zerssen) will be documented,
too. For studies which do not provide any response data
the proportion of responders will be estimated from
metric variables [29]. Extraction of studies included in
existing meta-analyses will be cross-checked with the
data used for effect size calculations in these reviews.
Quality assessment
Internal validity/Risk of bias
The Cochrane Collaboration`s tool for assessing risk of
bias will be used to assess the internal validity of the
included studies [30]. This tool addresses sequence
generation, allocation concealment, blinding of partici-
pants, personnel and outcome assessors, incomplete
outcome data, selective outcome reporting, and other
sources of bias. To assist the assessment standardized
instructions have been developed based on the general
instructions in the Cochrane handbook adapted for
our purposes. These instructions will be updated as
necessary (mainly if new, unpredicted issues come up).
An overall assessment of bias will be performed by
classifying all studies in the categories of low, unclear,
and high risk of bias.
External validity
External validity (generalizability) will be addressed by
documenting study setting, patient selection criteria,
patient characteristics, clinical relevance of outcomes,
length of follow-up, adverse effects, and discontinuation
rates.
Procedures and consequences of quality assessment
S t u d yq u a l i t yw i l lb ea s s e s s e di n d e p e n d e n t l yb yt w o
reviewers. Disagreements will be recorded and resolved
by discussion.
If considerable methodological heterogeneity is pre-
sent, subgroup analyses will be performed through
comparing the findings between studies of low and
unclear or high risk of bias.
Synthesis of information from primary studies
Calculation of effect size estimate for single trials
For dichotomous effectiveness outcomes (response,
remission, relapse) the ratio (with 95% confidence inter-
vals) of responder proportions will be calculated (using
both an intention to treat and a per protocol approach).
The main outcome measure is response after comple-
tion of acute phase treatment. For continuous outcomes
(depression scores) mean differences and standardized
mean differences and their 95% confidence intervals will
be calculated based on intention to treat data, available
case data and per protocol data. As we assume that
intention to treat data for continuous measures will not
be available for a number of studies we will use a prefer-
ence approach for collecting data for the primary meta-
analysis (first preference intention to treat data, second
preference available cases data, third preference per pro-
tocol data). For sensitivity analyses effect sizes will also
be calculated assuming a fixed difference between the
actual mean for the missing data and the mean assumed
by the analysis [30]. For rare outcomes and safety out-
comes (number of patients with adverse effects; discon-
tinuation for any reasons, for lack of improvement or
for adverse effect) odds ratios will be calculated.
Grouping experimental and control interventions for
comparisons
If possible we will perform analyses on single pharmaco-
logical agents (e.g., citalopram) but we expect that the
number of trials per agent performed in primary care
will usually be very small. Therefore, we consider to
categorize pharmacological interventions into five
groups: 1) tricyclic and tetracyclic antidepressants; 2)
selective serotonine reuptake inhibitors, 3) monoamino-
oxidase inhibitors, 4) newer agents such as venlafaxine
or mirtazepine, 5) hypericum extracts. If the literature
search reveals further relevant groups the protocol will
be amended. Typical comparator groups in the trials of
these agents are either another pharmacological agent
or placebo. The overwhelming majority of the trials of
pharmacological trials are dealing with acute phase
treatment and have durations up to 12 weeks.
Trials on psychological interventions are clinically
highly heterogeneous. Existing meta-analyses [11,12]
performed primary analyses on all types of interventions
with subgroup analyses for cognitive behavioural ther-
apy, problem solving therapy and other therapies. Com-
parator groups (usual care, waiting list, placebo,
pharmacological intervention) and study duration are
also highly variable. Without an in-depth analysis of the
available studies we feel yet unable to predefine an exact
grouping scheme. However, we plan to form groups of
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interventions for the primary analysis instead of combin-
ing all highly heterogeneous interventions and
comparators.
Calculation of pooled effect size estimates for direct
comparisons
Meta-analyses (random effects model, inverse variance
weighting) will be performed for direct comparisons of
single interventions and groups of similar interventions
and comparators (for example, SSRIs vs. tricyclics, SSRI
vs. hypericum extracts, SSRIs vs. placebo etc.) and
defined time-windows (up to 3 months and above). Pri-
mary analyses will be based on intention to treat data
for dichotomous outcomes and on the preference
approach described above for continuous data. We plan
to use the random effects model rather than the fixed
effects model, because we assume that the included stu-
dies will not be functionally equivalent and will show
considerable clinical (concerning population, interven-
tion) and methodological (design, quality etc.) heteroge-
neity. Statistical heterogeneity between study results will
be tested for significance using Cochran’sQt e s ta n d
quantified using the I
2 statistic. Results will be visually
displayed as forest plots. We will adjust for funnel plot
asymmetry using a method by Rücker et al. [31,32].
Subgroup and sensitivity analyses
A priori defined subgroup analyses will be performed
according to diagnosis (trials restricted to patients meet-
ing criteria of major depression and other trials) and
risk of bias (low vs. unclear/high risk). Sensitivity ana-
lyses will be performed using available cases and per
protocol data. For continuous outcomes we will also
perform a sensitivity analysis in which corrected means
(see above) are used for trials with missing data which
did not use an intention to treat analysis.
Meta-regression analyses
In case of considerable heterogeneity between study
results in a specific comparison that cannot be explained
by the defined subgroups, a series of a posteriori
(explorative) meta-regression analyses will be performed
to identify sources of heterogeneity. All meta-regression
analyses will be performed using the restricted maxi-
mum likelihood estimate method.
Multiple treatment meta-analysis
If possible we aim to perform a multiple treatment
meta-analysis in which several interventions will be
compared simultaneously [33,34]. We expect that this
will be possible for the pharmacological interventions
reviewed as trials are likely to use similar methodology
(comparators, duration, outcome measures). We are
uncertain whether it will be possible to include psycho-
logical interventions as the information available to us
suggests that these trials are very different from trials of
pharmacological agents. However, comparing different
psychological interventions could be an option. Due to
these uncertainties all multiple treatment meta-analyses
will be considered as exploratory. The analyses will be
done within a Bayesian framework using WinBUGS
code following Lu and Ades [35]. Results will be inter-
preted in the way described by Salanti et al. [36]. Before
the analyses will be initiated details of the methods will
be predefined in an analysis plan.
Discussion
Practitioners do not only want to know whether there is
evidence that a specific treatment is more effective than
placebo, but also how the treatment options compare to
each other. Therefore, we believe that a multiple treat-
ment systematic review of primary-care based rando-
mized controlled trials on the most important therapies
against depression is timely. We assume that a formal
multiple-treatment meta-analysis will be possible for
comparing selective serotonine reuptake inhibitors
(SSRIs), tricyclic antidepressants, and hypericum
extracts. Our preliminary analysis of the literature sug-
gests that it might be difficult to include psychological
treatments into the formal meta-analytic comparison.
Trials on psychological interventions typically use other
control groups (usual care, waiting lists or not clearly
defined pharmacological treatment) than trials on phar-
macological interventions (which are usually placebo-
controlled or compare two pharmacological treatments),
tend to have longer duration and often use other mea-
surement scales. While multiple treatment meta-analysis
gains considerable popularity it is associated with con-
siderable methodological problems and based on strong
assumptions [27]. Therefore, our project will also be a
case study to investigate whether multiple treatment
meta-analysis can be applied to answer the important
question which antidepressant treatment is most effec-
tive in the primary care setting.
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